Related Experiment Video
Updated: Jul 11, 2026
04:22
Assessment of Knee Hyperalgesia in Mice using Pressure Application Measurement
Published on: June 13, 2025
Hypoalgesia in mice lacking GABA transporter subtype 1
Yin Fang Xu1, You Qing Cai, Guo Qiang Cai
1Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, SIBS, CAS, Shanghai, China.
Journal of Neuroscience Research
|October 9, 2007
Summary
Genetic knockout or inhibition of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) reduces pain sensitivity in mice. This suggests GAT1 inhibitors could be a potential new therapy for pain management.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- Gamma-aminobutyric acid (GABA) transporters regulate GABA neurotransmission.
- GABA transporter 1 (GAT1) is the primary GABA transporter in the central nervous system (CNS).
- Previous studies indicated that GAT1 overexpression induces hyperalgesia (increased pain sensitivity) in mice.
Purpose of the Study:
- To investigate the role of GAT1 in pain perception.
- To evaluate the analgesic potential of GAT1 inhibitors.
Main Methods:
- Comparison of nociceptive responses in GAT1-knockout, heterozygous, and wild-type mice.
- Utilized four standard pain models: tail-immersion, hot-plate, acetic acid-induced abdominal constriction, and formalin tests.
- Assessed the analgesic effects of GAT1-selective inhibitors (NO-711 and tiagabine) across all genotypes.
Main Results:
- GAT1 deficiency, achieved through genetic knockout, resulted in hypoalgesia (reduced pain sensitivity).
- Pharmacological blockade of GAT1 using selective inhibitors also led to hypoalgesia.
- These effects were consistent across the different pain models and mouse genotypes.
Conclusions:
- GAT1 plays a critical role in modulating the nociceptive threshold.
- GAT1 deficiency or inhibition confers hypoalgesia.
- GAT1 inhibitors demonstrate potential for clinical application in pain therapy.
